EDN1 and idiopathic pulmonary fibrosis: A large number of these patients do not have PH; and whereas treatment with bosentan, an endothelin-1 antagonist, was effective to treat idiopathic pulmonary arterial hypertension, it did not produce improvement in patients with IPF and PH [23].